N

Nippon Shinyaku Co Ltd
TSE:4516

Watchlist Manager
Nippon Shinyaku Co Ltd
TSE:4516
Watchlist
Price: 3 988 JPY 0.15% Market Closed
Market Cap: 268.7B JPY
Have any thoughts about
Nippon Shinyaku Co Ltd?
Write Note

Nippon Shinyaku Co Ltd
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Nippon Shinyaku Co Ltd
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
N
Nippon Shinyaku Co Ltd
TSE:4516
Total Equity
ÂĄ234.9B
CAGR 3-Years
10%
CAGR 5-Years
11%
CAGR 10-Years
10%
Takeda Pharmaceutical Co Ltd
TSE:4502
Total Equity
ÂĄ6.9T
CAGR 3-Years
9%
CAGR 5-Years
7%
CAGR 10-Years
11%
Daiichi Sankyo Co Ltd
TSE:4568
Total Equity
ÂĄ1.6T
CAGR 3-Years
7%
CAGR 5-Years
5%
CAGR 10-Years
5%
Otsuka Holdings Co Ltd
TSE:4578
Total Equity
ÂĄ2.5T
CAGR 3-Years
8%
CAGR 5-Years
8%
CAGR 10-Years
5%
Chugai Pharmaceutical Co Ltd
TSE:4519
Total Equity
ÂĄ1.6T
CAGR 3-Years
15%
CAGR 5-Years
15%
CAGR 10-Years
11%
Astellas Pharma Inc
TSE:4503
Total Equity
ÂĄ1.5T
CAGR 3-Years
3%
CAGR 5-Years
3%
CAGR 10-Years
2%
No Stocks Found

Nippon Shinyaku Co Ltd
Glance View

Market Cap
268.7B JPY
Industry
Pharmaceuticals

Nippon Shinyaku Co., Ltd. stands as a beacon in the Japanese pharmaceutical landscape, weaving a story that begins over a century ago. Originally founded to address the medical needs of its society, the company has strategically evolved its focus, channeling its expertise into two main business domains: pharmaceuticals and functional food. As it carved its niche, Nippon Shinyaku harnessed the power of innovation and research to develop drugs that address critical medical needs, especially in oncology, hematology, and rare diseases. This specialization not only strengthens its foothold but also embodies a moral commitment to enhancing patient quality of life, proving profitable as these fields often present less competition but promise high demand and returns. Alongside its pharmaceutical ventures, Nippon Shinyaku has leveraged the burgeoning wellness trend through its functional food segment, offering products that promote health and prevent disease. This dual approach leverages the company's bioscience expertise and diversifies its revenue streams, shielding it from the volatility often seen in the pharmaceutical sector. By making strategic alliances and collaborations, both domestically and overseas, Nippon Shinyaku accelerates its market penetration and expands its international footprint. As it capitalizes on its robust R&D capabilities, the company anchors its success on a fusion of scientific advancement and strategic acumen, crafting a narrative of resilience and adaptability in a rapidly evolving industry.

Intrinsic Value
4 781.58 JPY
Undervaluation 17%
Intrinsic Value
Price
N

See Also

What is Nippon Shinyaku Co Ltd's Total Equity?
Total Equity
234.9B JPY

Based on the financial report for Sep 30, 2024, Nippon Shinyaku Co Ltd's Total Equity amounts to 234.9B JPY.

What is Nippon Shinyaku Co Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
10%

Over the last year, the Total Equity growth was 11%. The average annual Total Equity growth rates for Nippon Shinyaku Co Ltd have been 10% over the past three years , 11% over the past five years , and 10% over the past ten years .

Back to Top